A New Way to
Detect Cancer
DELFI at AACR 2023
As a next-generation liquid biopsy company, DELFI Diagnostics is developing a rich pipeline of products designed to save lives by detecting cancer at its earliest stages. Our whole-genome fragmentomics platform is capable of supporting a broad range of high-performing applications to address major unmet medical needs in cancer.
Come see our presentations at AACR or stop by Booth 3355 to learn more about DELFI and our rigorous, sustainable approach to delivering new, better solutions to patients, providers, and health systems.
ORAL PRESENTATIONS
Prospective evaluation of cell-free DNA fragmentomes for lung cancer detection
Session Title: Behavioral and Biological Opportunities to Improve Cancer Prevention, Early Detection, and Disparities
Session Date/Time: 4/18/23, 2:52 PM – 3:07 PM ET
Room: W304 E-H – Convention Center
Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer
Session Title: Increasing the Clinical Utility of Cell-Free DNA Testing
Session Date/Time: 4/18/23, 3:52 PM – 4:07 PM ET
Room: Valencia D – Convention Center
POSTER PRESENTATIONS
Early detection of ovarian cancer using cell-free DNA fragmentomes
Session Title: Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment
Session Date and Time:4/16/23, 1:30 PM – 5:00 PM ET
Location: Section 28
Poster Board Number: 15
CASCADE-LUNG: Validation of a blood-based assay that evaluates cell-free DNA fragmentation patterns to detect lung cancer
Session Title: Phase II and Phase III Clinical Trials in Progress
Session Date and Time: 4/17/23, 9:00 AM – 12:30 PM ET
Location: Section 46
Poster Board Number: 26